View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2022

Daiichi Sankyo commences Phase I/II/III trial for Covid-19 booster in Japan

The trial will assess the safety and efficacy of the booster vaccine in healthy adult subjects in Japan.

Daiichi Sankyo has commenced a Phase I/II/III clinical trial of a booster dose of Covid-19 vaccine, DS-5670, in Japan.

The messenger ribonucleic acid (mRNA) vaccine leverages a new nucleic acid delivery technology.

In animal models, the vaccine elicited neutralising activities against the Omicron variant of the SARS-CoV-2 virus to some extent after the initial dosing.

Furthermore, the additional dose of the vaccine boosted neutralising activities, showing a possible booster effect.

The trial will assess the safety and efficacy of the booster vaccine in healthy Japanese adults, including elderly people, who completed the initial two-dose regimen with Covid-19 vaccines.

Booster vaccine will be given a minimum of six months following the last vaccine dose.

The trial’s first part will decide the recommended booster dosage of the vaccine followed by a controlled trial that will enrol 4,500 adult subjects to assess DS-5670 against other vaccines in the country.

Daiichi Sankyo plans to develop and market the DS-5670 vaccine in Japan this year.

The vaccine’s clinical development is being carried out through Japan Agency for Medical Research and Development (AMED)-promoted “Vaccine development project” and “Urgent improvement project for vaccine manufacturing systems” supported by the Ministry of Health, Labour and Welfare.

In December last year, the company dosed the first subject in the Phase III DESTINY‑Breast11 clinical trial of Enhertu (trastuzumab deruxtecan) in patients with breast cancer.

This trial is intended to evaluate Enhertu as neoadjuvant therapy for high-risk human epidermal growth factor receptor 2 (HER2) positive early-stage breast cancer.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy